Precision2

• Research type

  Research Study

• Full title

  Early Detection of Hepatocellular Carcinoma (HCC) in Cirrhotic Patients using Quantitative Multiparametric MRI

• IRAS ID

  300968

• Contact name

  Rajarshi Banerjee

• Contact email

  rajarshi.banerjee@perspectum.com

• Sponsor organisation

  Perspectum Ltd

• Duration of Study in the UK

  5 years, 0 months, 1 days

• Research summary

  The incidence of hepatocellular carcinoma (liver cancer) is on the rise globally, driven by cirrhosis, obesity and viral hepatitis. Survival rates have improved with optimised allocation and refinement of treatment options including surgical resection, radiofrequency ablation, embolisation, chemotherapy and targeted molecular therapies including immunotherapy.

  The central question of this study is can early detection and long term outcomes be improved by using MRI based surveillance instead of the current standard of care ultrasound based surveillance. The key motivation of this study is to help patients access the most suitable treatment combinations, based on early diagnosis using quantitative MRI and the integration of clinical, radiological, transcriptomic and genomic data.

• REC name

  North of Scotland Research Ethics Committee 2

• REC reference

  21/NS/0087

• Date of REC Opinion

  14 Jul 2021

• REC opinion

  Unfavourable Opinion